Jing Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Yu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jiaguo Li
Shanghai Cell therapy Group Co., Ltd, Shanghai, China
1 shared publication - Jianyao Zeng
School of Medicine, Shanghai University, Shanghai, China
1 shared publication - Qian Huang
Shanghai Cell therapy Group Co., Ltd, Shanghai, China
1 shared publication - Qijun Qian
School of Medicine, Shanghai University, Shanghai, China
1 shared publication - Tao Liu
Biological Therapy Center, Shanghai Mengchao Cancer Hospital, Shanghai University , Shanghai 201805
1 shared publication - Weimin Zhu
Shanghai Cell therapy Group Co., Ltd, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 28 May 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (29) , 2244-2252
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
The combination of programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies has potential for enhancing clinical efficacy. We described the development and antitumor activity of Z15-0, a bispecific nanobody targeting both the PD-1 and CTLA-4 pathways simultaneously. We designed and optimized the mRNA sequence encoding Z15-0, referred to as Z15-0-2 and through a series of in vitro and in vivo experiments, we established that the optimized Z15-0-2 mRNA sequence significantly increased the expression of the bispecific nanobody. Administration of Z15-0-2 mRNA to tumor-bearing mice led to greater inhibition of tumor growth compared to controls. In aggregate, we introduced a novel bispecific nanobody and have re-engineered it to boost expression of mRNA, representing a new drug development paradigm.
- 28 May 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (29) , 2244-2252
Open AccessAntitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
The combination of programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies has potential for enhancing clinical efficacy. We described the development and antitumor activity of Z15-0, a bispecific nanobody targeting both the PD-1 and CTLA-4 pathways simultaneously. We designed and optimized the mRNA sequence encoding Z15-0, referred to as Z15-0-2 and through a series of in vitro and in vivo experiments, we established that the optimized Z15-0-2 mRNA sequence significantly increased the expression of the bispecific nanobody. Administration of Z15-0-2 mRNA to tumor-bearing mice led to greater inhibition of tumor growth compared to controls. In aggregate, we introduced a novel bispecific nanobody and have re-engineered it to boost expression of mRNA, representing a new drug development paradigm.